MOUNTAIN VIEW, CA --(Marketwired - February 29, 2016) - VIVUS, Inc. (
Date: March 9, 2016 Time: 4:30 PM EST
Listen via Internet: http://ir.vivus.com/
Webcast Link: http://edge.media-server.com/m/p/3aysciy5
Dial in: 1 224 357-2386 Dial in (Toll-Free): 1 877-359-2916 Audience Passcode: 5812 2612
A webcast replay will be available on the VIVUS website for 30 days.
VIVUS is a biopharmaceutical company commercializing and developing innovative, next-generation therapies to address unmet needs in obesity, sleep apnea, diabetes and sexual health. For more information about the company, please visit www.vivus.com .
Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimate," "expect," "intend," "likely," "may," "plan," "potential," "predict," "opportunity" and "should," among others. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. VIVUS does not undertake an obligation to update or revise any forward-looking statements. Investors should read the risk factors set forth in VIVUS's Form 10-K for the year ended December 31, 2014 as filed on February 25, 2015 and as amended by the Form 10-K/A filed on April 30, 2015, and periodic reports filed with the Securities and Exchange Commission.
CONTACT: VIVUS, Inc. Mark Oki Chief Financial Officer 650-934-5268 oki@vivus.com The Trout Group Brian Korb (Managing Director) 646-378-2923 bkorb@troutgroup.com